CO2022014343A2 - Composiciones y métodos para el tratamiento de lesión o hemorragia por reperfusión después de la terapia de recanalización - Google Patents
Composiciones y métodos para el tratamiento de lesión o hemorragia por reperfusión después de la terapia de recanalizaciónInfo
- Publication number
- CO2022014343A2 CO2022014343A2 CONC2022/0014343A CO2022014343A CO2022014343A2 CO 2022014343 A2 CO2022014343 A2 CO 2022014343A2 CO 2022014343 A CO2022014343 A CO 2022014343A CO 2022014343 A2 CO2022014343 A2 CO 2022014343A2
- Authority
- CO
- Colombia
- Prior art keywords
- methods
- reperfusion injury
- hemorrhage
- compositions
- thrombolytic
- Prior art date
Links
- 206010063837 Reperfusion injury Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 208000032843 Hemorrhage Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 238000013151 thrombectomy Methods 0.000 abstract 4
- 239000003527 fibrinolytic agent Substances 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000032382 Ischaemic stroke Diseases 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002537 thrombolytic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a composiciones farmacéuticas y métodos para tratar el accidente cerebrovascular isquémico en seres humanos, utilizando un derivado de tetrafluorobencilo de fórmula (I) o una de sus sales farmacéuticamente aceptable junto con un fármaco trombolítico, trombectomía endovascular o ambos (por ejemplo, trombectomía endovascular y un trombolítico). droga). La administración de un derivado de tetrafluorobencilo de fórmula (I) o su sal farmacéuticamente aceptable puede reducir el daño por reperfusión y otros eventos adversos en pacientes que reciben conjuntamente un fármaco trombolítico, trombectomía endovascular o trombectomía endovascular con un fármaco trombolítico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062988187P | 2020-03-11 | 2020-03-11 | |
PCT/IB2021/000136 WO2021181159A1 (en) | 2020-03-11 | 2021-03-10 | Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2022014343A2 true CO2022014343A2 (es) | 2023-02-16 |
Family
ID=77665492
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2022/0014343A CO2022014343A2 (es) | 2020-03-11 | 2022-10-07 | Composiciones y métodos para el tratamiento de lesión o hemorragia por reperfusión después de la terapia de recanalización |
Country Status (12)
Country | Link |
---|---|
US (2) | US11826329B2 (es) |
EP (1) | EP4117648A4 (es) |
JP (1) | JP2023517566A (es) |
KR (1) | KR20230010187A (es) |
CN (1) | CN115515573A (es) |
AU (1) | AU2021233206A1 (es) |
BR (1) | BR112022018136A2 (es) |
CA (1) | CA3174709A1 (es) |
CO (1) | CO2022014343A2 (es) |
IL (2) | IL309923A (es) |
MX (1) | MX2022011214A (es) |
WO (1) | WO2021181159A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115515573A (zh) | 2020-03-11 | 2022-12-23 | Gnt制药有限公司 | 用于治疗再通疗法之后再灌注损伤或出血的组合物和方法 |
WO2023156808A2 (en) * | 2021-12-28 | 2023-08-24 | Gnt Pharma Co., Ltd. | Compositions and methods for treating pulmonary disorders |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2490120C (en) * | 2002-06-19 | 2010-06-01 | Neurotech Co., Ltd. | Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same |
KR100522188B1 (ko) * | 2003-01-20 | 2005-10-18 | 주식회사 뉴로테크 | 뉴로트로핀에 의해 유도되는 세포괴사 억제 방법 |
KR20060121721A (ko) | 2005-05-23 | 2006-11-29 | 주식회사 중외제약 | 테트라플루오로벤질 유도체 또는 그의 염을 함유하는주사제용 조성물 |
KR101523345B1 (ko) | 2008-04-28 | 2015-05-28 | 주식회사 지엔티파마 | 재관류 손상의 치료 또는 예방용 약학 조성물 |
CN102617383A (zh) | 2012-03-20 | 2012-08-01 | 横店集团家园化工有限公司 | 索法地尔晶型、制备方法及包含索法地尔晶体的无菌粉末 |
CN115515573A (zh) | 2020-03-11 | 2022-12-23 | Gnt制药有限公司 | 用于治疗再通疗法之后再灌注损伤或出血的组合物和方法 |
-
2021
- 2021-03-10 CN CN202180032761.3A patent/CN115515573A/zh active Pending
- 2021-03-10 JP JP2022554288A patent/JP2023517566A/ja active Pending
- 2021-03-10 IL IL309923A patent/IL309923A/en unknown
- 2021-03-10 MX MX2022011214A patent/MX2022011214A/es unknown
- 2021-03-10 IL IL296288A patent/IL296288B2/en unknown
- 2021-03-10 WO PCT/IB2021/000136 patent/WO2021181159A1/en unknown
- 2021-03-10 KR KR1020227034966A patent/KR20230010187A/ko unknown
- 2021-03-10 EP EP21768391.1A patent/EP4117648A4/en active Pending
- 2021-03-10 AU AU2021233206A patent/AU2021233206A1/en active Pending
- 2021-03-10 CA CA3174709A patent/CA3174709A1/en active Pending
- 2021-03-10 US US17/197,736 patent/US11826329B2/en active Active
- 2021-03-10 BR BR112022018136A patent/BR112022018136A2/pt unknown
-
2022
- 2022-10-07 CO CONC2022/0014343A patent/CO2022014343A2/es unknown
-
2023
- 2023-08-21 US US18/235,986 patent/US20230390231A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4117648A4 (en) | 2024-05-29 |
IL296288A (en) | 2022-11-01 |
IL309923A (en) | 2024-03-01 |
US20230390231A1 (en) | 2023-12-07 |
MX2022011214A (es) | 2022-10-07 |
CN115515573A (zh) | 2022-12-23 |
KR20230010187A (ko) | 2023-01-18 |
CA3174709A1 (en) | 2021-09-16 |
WO2021181159A1 (en) | 2021-09-16 |
BR112022018136A2 (pt) | 2022-10-25 |
IL296288B1 (en) | 2024-02-01 |
AU2021233206A1 (en) | 2022-10-06 |
IL296288B2 (en) | 2024-06-01 |
US11826329B2 (en) | 2023-11-28 |
US20210283080A1 (en) | 2021-09-16 |
EP4117648A1 (en) | 2023-01-18 |
JP2023517566A (ja) | 2023-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2022014343A2 (es) | Composiciones y métodos para el tratamiento de lesión o hemorragia por reperfusión después de la terapia de recanalización | |
CO2022012975A2 (es) | Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead | |
CL2022001625A1 (es) | Derivados de pirazolilo útiles como agentes anti-cancerígenos | |
AR107871A1 (es) | Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos | |
AR092857A1 (es) | Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas | |
NI201700101A (es) | Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina | |
CL2019003091A1 (es) | Terapia de combinación. | |
GT200000184A (es) | Composiciones para facilitar el crecimiento de la piel y metodos y articulos que la emplean. | |
CO2022002842A2 (es) | Degradadores bifuncionales de brd9 y sus métodos de uso | |
AR057946A1 (es) | Formulacion de zonisamida de liberacion sostenidda | |
CL2019001366A1 (es) | Formulaciones tamponadas exendina (9-39). | |
CL2019000768A1 (es) | Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos. | |
CO2022005999A2 (es) | Inhibidores del factor d del complemento para administración oral | |
CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
AR127247A1 (es) | Inhibidores de cdk2 de ciclopentilpirazol | |
ECSP19084722A (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
CO2019002616A2 (es) | Compuestos de indazol para usar en lesiones de tendones y/o ligamentos | |
AR127533A1 (es) | INHIBIDORES DEL SARS-CoV-2 PARA EL TRATAMIENTO DE INFECCIONES POR CORONAVIRUS | |
CL2021000627A1 (es) | Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular | |
CO2022012880A2 (es) | Composiciones de palmitato de vitamina a, procesos para su preparación, usos y métodos que las componen | |
AR108792A1 (es) | Composiciones que comprenden timolol | |
CL2020002398A1 (es) | Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd") | |
AR128051A1 (es) | Inhibidores de parp1 | |
CO2023017669A2 (es) | Terapia combinada anti-vhc ventajosa | |
CL2023001677A1 (es) | Inmunocitoquina para activar el receptor il-10ra humano y su uso |